Name：Cheng Wang
Position：lecturer
Email：wangcheng@ncu.edu.cn
Native place：Jiangxi Jian
Mentor type：Postgraduate tutor
Main courses taught：Clinical pharmacology
Major research direction
1、Design, synthesis and activity evaluation of small molecule inhibitors targeting triple-negative breast cancer；
2、Rational drug design and research based on natural products。
Education experience
2012.9~2016.7：China Pharmaceutical University，Traditional Chinese Medicine Major，Bachelor of Science
2016.9~2022.7：China Pharmaceutical University，Natural Medicinal Chemistry Major，Doctor of Science
Work experience
2022.7~ Present：College of Pharmacy, Nanchang University (Institute of Clinical Pharmacology), Lecturer.
Academic part-time job
Executive Committee Member of the Pharmaceutical Chemistry Professional Committee of Jiangxi Provincial Pharmaceutical Association
Member of the Intelligent Decision-making Subsection for Comprehensive Evaluation of Traditional Chinese Medicine of the Chinese Society for Information on Traditional Chinese Medicine
Personal Honor
Selected as a provincial-level talent in 2024
Major achievement
I have been the principal investigator of one national natural science foundation project and three provincial natural science foundation projects. In recent years, I have published numerous research papers as the first author or corresponding author in well-known international and domestic pharmaceutical chemistry journals such as J Med Chem, Eur J Med Chem, and Bioorgan. Chem. I have also applied for 4 invention patents and obtained 1 patent authorization.
1、 Research Project
[1] A dual inhibitor of PARP1/EZH2 based on synthetic lethal design for precise treatment of BRCA wild-type triple-negative breast cancer. National Natural Science Foundation of China - Youth Fund Project，2024.01-2026.12, 82304290.
[2] The design of the PARP/MEK dual inhibitor is aimed at treating tumors with RAS mutations. The Training Program for Key Academic and Technical Leaders in Major Disciplines in Jiangxi Province, 2024.01-2026.12.
[3] Design, synthesis and anti-breast cancer activity study of selective PARP1/CDK6 dual-target inhibitors. Jiangxi Province Natural Science Foundation General Project, 2023.07-2026.06, 20232BAB206176.
2、Publish representative papers
[1] Heqing Fan…Cheng Wang*(corresponding author), Discovery of selective PARP1/EZH2 inhibitor inducing PANoptosis in triple-negative breast cancer, Eur J Med Chem, 2026, 302(Part 2): 1182287.
[2] Jingting Zeng…Cheng Wang*(corresponding author), Design and Synthesis of Novel MEK Inhibitors for the Treatment of Solid Tumors, Chem Biol Drug Des. 2025, 105: 2.
[3] Cheng Wang (first author), Heng Luo, Xinye Chen, et al. Discovery of dual PARP and CDK6 inhibitors for triple-negative breast cancer with wild-type BRCA [J]. Bioorg Chem, 2023, 139: 106683.
[4] Cheng Wang (first author), …et al. Discovery of Precision Targeting EZH2 Degraders for Triple-Negative Breast Cancer [J]. Eur J Med Chem, 2022, 238: 114462.
[5] Cheng Wang (first author), … et al. Discovery of First-in-Class Dual PARP and EZH2 Inhibitors for Triple-Negative Breast Cancer with Wild-Type BRCA [J]. J Med Chem, 2021, 64(17): 12630-12650. (Cover Article).
[6] Cheng Wang (first author), … et al. Design and SAR of Withangulatin A Analogues that Act as Covalent TrxR Inhibitors through the Michael Addition Reaction Showing Potential in Cancer Treatment [J]. J Med Chem, 2020, 63(19): 11195-11214. (Cover Article).
3、Authorized patent
[1] Dual-target PARP/EZH2 inhibitor, preparation method and application. Inventors: Kong Lingyi, Wang Xiaobing, Wang Cheng. Patent authorization number: CN 113024516 B.
4、Talent cultivation
[1] As the first instructor, I guided students Lai Yiling and others to win the national third prize in the 10th National College Students' Life Science Competition (Scientific Inquiry Category)；
[2] As the first instructor, I guided students Li Xiaoting and others to win the second prize in the Jiangxi Province category of the 9th National College Students' Life Science Competition (Scientific Inquiry Category)。
Cn
